Physician profile
Katherine D Simpson
NPI 1073073029
$3,512.42
in general payments reported to CMS, 2019-2025
27 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $1,087 · 2023: $656 · 2024: $1,102 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $410.92 | 2024-2025 | Epclusa, Vemlidy |
| Inspire Medical Systems, INC. | $250.96 | 2023-2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $229.27 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Teva Pharmaceuticals USA, INC. | $205.61 | 2022-2023 | Uzedy |
| Scynexis, INC. | $171.26 | 2022 | |
| Paratek Pharmaceuticals, INC. | $155.86 | 2022 | |
| Averitas Pharma INC. | $133.88 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $123.16 | 2024 | |
| Corcept Therapeutics | $122.98 | 2025 | Korlym |
| Stemline Therapeutics INC. | $121.82 | 2022 | |
| Viiv Healthcare Company | $121.11 | 2024 | Apretude |
| Janssen Pharmaceuticals, INC | $120.14 | 2021 | |
| Abbvie INC. | $117.88 | 2022 | |
| Axsome Therapeutics, INC. | $116.64 | 2025 | Auvelity |
| Genzyme Corporation | $112.88 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $105.86 | 2022 | |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Alexion Pharmaceuticals, INC. | $98.44 | 2023 | |
| Idorsia Pharmaceuticals US INC | $96.19 | 2022 | |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Heron Therapeutics, INC. | $80.77 | 2023 | Zynrelef |
| Molnlycke Health Care US, LLC | $77.39 | 2024 | Avance |
| Pacira Pharmaceuticals Incorporated | $68.14 | 2024 | Exparel |
| Acacia Pharma INC | $63.45 | 2022 | |
| Sk Life Science, INC. | $60.65 | 2022 | |
| Coloplast Corp | $53.83 | 2023 | Titan, Altis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.